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Key learning points: 
 We explored UK patient preferences for treatment of epilepsy 
 Our study involved a qualitative component, followed by a large-scale survey 
 Participants had clearly-formed views and preferences for care, reflecting their personal 
characteristics and life contexts 
 Practitioners need to be mindful of these in discussions about care 
 Patients deserve access to high quality evidence about effectiveness of different treatments 
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The widening range of treatment options for epilepsy, and their potential outcomes, mean decisions 
about treatment for people with epilepsy are often complex. While antiepileptic drugs (AEDs) 
represent the mainstay of treatment, other potential non-drug interventions are gaining in 
importance. These treatments all have the potential for harming those using them, as well as 
bringing benefits. 
This study examined the views and experiences of people with epilepsy (PWE) about a range of 
treatment options. We used both qualitative and quantitative approaches – a series of depth-
narrative interviews, followed by a large-scale survey.  Treatment options and healthcare priorities 
deemed important by at least 10% of interview participants were then addressed as a series of 
statements in the follow-on survey questionnaire. Quantitative responses supported health care 
priorities identified through the qualitative interviews. 
The key goal of treatment among study participants was to be able to live ‘a normal life’. Important 
physical, psychological and life benefits of treatment were identified – most being the direct 
consequence of improved seizure control. One psychological benefit, reduced worry, was also 
identified as an important treatment goal. 
All participants viewed AEDs as appropriate first-line treatment; and since adverse effects of AEDs 
had implications for individual levels of daily function and wellbeing, their appropriate management 
was considered important. In contrast, surgery was almost always regarded as the treatment of last 
resort. Despite lack of research evidence supporting their use, participants were interested in 
complementary therapies as adjunctive treatment and a means of coping with having epilepsy, with 
yoga and meditation of particular interest. An important finding was the desire for targeted services 
to help with memory problems, as was the call to increase availability of psychological/counselling 
services.  
Our findings emphasise the importance of providing treatment responsive to the life context of 
individual patients. They highlight not only the level of demand for specific treatment options, but 
also the need for high-quality evidence to support future investment in their provision. 
 

















Neurological conditions are a key priority for research into patient care in the UK (1). Epilepsy is the 
most common of serious neurological conditions, affecting an estimated six million people in the 
European Region and around 600,000 people in England (2,3), who have to live daily with its socio-
medical repercussions. Most people given a diagnosis of epilepsy are treated with antiepileptic drugs 
(AEDs), of whom 60-70% will achieve remission from seizures (4,5). The remainder will continue to 
have seizures and experience the consequences of a chronic disabling and potentially stigmatising 
condition (6,7).  Achieving remission, however, may come at the cost of adverse medication effects, 
including common dose-related effects such as weight gain or low mood, rare but potentially life-
threatening events such as psychosis, and long-term effects including memory problems. A third of 
people treated for epilepsy are women of childbearing age; and a growing body of evidence shows 
their children to be at increased risk of congenital abnormalities and neuro-developmental problems 
(8-11).  
While AEDs are the mainstay of clinical treatment for epilepsy, other potential non-drug 
interventions of increasing importance include surgery (12) and vagal nerve stimulation (13). 
Recently, there has been a resurgence of interest in dietary control of refractory seizures (14-16). The 
role of psychological treatment programmes for seizure control, such as Relaxation Therapy, 
Cognitive Behavioural Therapy and Biofeedback, is also being explored (17-19); as is that of 
alternative therapies such as yoga (20) and Chinese traditional medicine (21). For management of 
common co-morbidities and quality of life impacts, available treatments include psychological and 
educational interventions and counselling (18,19,22-27). All these treatments have potential costs to 
those using them, as well as benefits. For example, surgery has been shown to have potential 
detrimental effects for cognitive function and memory (28); and psychosocial outcomes are poorer 
for those not achieving complete seizure freedom (29). Likewise, though tolerability to it generally 
improves over time, there are short-term adverse effects associated with VNS (30); and dietary 
control requires careful monitoring to avoid possible nutritional deficits (31).  
The wide range of treatment options and their potential outcomes mean treatment decisions for 
people with epilepsy (PWE) are often complex, involving careful consideration. That patients’ views 
about benefits and harms may differ from those of clinicians has been shown across a range of 
conditions (32-34). The cultural shift in the UK National Health Service from ‘medical dominance to 
managed consumerism’ (35) is reflected in policy documents highlighting the need for care to be 
planned around the specific needs and choices of individual patients (36,37) and to ascertain views 
and goals of users with regard to processes and outcomes of care. Users are now seen as having a 
central role in defining priorities for service provision and assessment of outcomes (38). Data about 
their preferences for treatments and treatment outcomes are important both in health technology 
assessment and healthcare prioritising initiatives (39).  
To date, little systematic empirical research has been undertaken to assess the views of PWE about 
treatment interventions and outcomes that are important to them. For example, the commonly 
applied criterion of success in drug trials is a 50% reduction in seizure frequency. This criterion is, 
however, arbitrary and not derived from judgements of PWE themselves (though previous work (40, 
41) shows a much greater reduction is required for meaningful QOL impacts). Similarly no attempt 
has been made to include patients’ views in definitions of what constitutes meaningful difference or 
lack of difference between treatments.  A small number of primary research-based studies have 
addressed these issues (42-47) and two Cochrane reviews have touched tangentially on them 
(48,49). However, understanding of what PWE themselves regard as key issues around the 
management of their condition and key outcomes of that management rests on an extremely thin 
evidence base.  
The over-arching aim of the project we report here was to explore the views and understandings 
about, and preferences for treatment, of adults with epilepsy; and hence address the question as to 
what constitutes appropriate epilepsy management. Since the implications of having epilepsy can 
vary considerably for different clinical trajectories and life contexts, we addressed these issues across 
three different patient subgroups, namely: 
a) adults with a recent diagnosis of epilepsy (diagnosis made at least three months but not 
longer than 12 months ago) 
b) adults with established epilepsy (diagnosis made more than 12 months ago) and on 
antiepileptic treatment 
c) as a separate group, women of childbearing potential (18 to 50 years) with early or 
established epilepsy.  
 
Our specific research objectives were to explore: 
1. which treatment interventions are considered important by people with epilepsy; and whether 
and how different patient subgroups prioritise different interventions; 
2. which outcomes of treatment interventions are considered important by people with epilepsy; and 
whether and how different patient subgroups prioritise different outcomes. 
The study received ethics approval from the UK National Research Ethics Service Committee North 
West on 3rd May 2011.  
Methods 
Overall study design: 
To address the above objectives, our study involved two separate phases. In Phase 1, a series of 
qualitative interviews were conducted with a small number of participants. This was followed in 
Phase 2 by a large-scale quantitative survey.  
In the first phase, we used in-depth-narrative interviews (50) to provide insights into how individual 
patient circumstances and life experience condition their concerns about treatment and its outcomes 
(51), followed by topic guided questions and a ranking exercise to examine which treatment 
interventions and outcomes were deemed important, and why. For this latter part of the interviews, 
participants were provided with a brief summary of each treatment along with information about its 
effectiveness – the aim being to allow those without any personal experience or knowledge of the 
treatment possibilities to give each meaningful consideration (see examples in Appendix 1). 
Expressed preferences were considered in relation to AEDs, surgery, vagal nerve stimulation, 
psychological interventions, including support for memory problems and use of complementary 
therapies. 
In the second phase, a web-based survey, hosted on the website of the UK patient organisation, 
Epilepsy Action, examined the generalisability of findings from the qualitative interviews and allowed 
further exploration of treatment preferences. Issues raised by 10% or more of participants in the 
qualitative study formed the basis of a series of preference statements for the survey, the precise 
wording of which was based on their own words. 
This second phase also involved a series of discrete choice experiments to elicit preferences 
specifically with regard to the attributes of different AEDs and to explore maximally acceptable risk 
for each AED outcome. The results from the DCE are reported separately elsewhere (52). 
Ethical approval for the study was given by the UK Health Research Authority NRES Committee North 
West. 
 Sampling and recruitment    
In the first phase we aimed to recruit a maximum of 60 patients, around 20 patients from each of the 
three groups described above. Purposive sampling methods (53) were used to achieve maximum 
variation in clinical and socio-demographic characteristics within each group. Inclusion and exclusion 
criteria are shown in Box 1. 
 
Inclusion criteria 
 An outpatient at one of three major UK epilepsy centres and meeting criteria for one of three 
defined groups (see above) 
 Aged 18 years and over 
 No other long-term health conditions 
 
Exclusion criteria:  
 Aged under 18 years 
 With learning difficulties sufficient as to make required tasks unreasonable 
 Non-English speaker 
 Currently participating in other research 
 Unable to provide informed consent 
 
 
Box 1: Sampling criteria for Phase 1  
Participants were identified by clinical staff at three specialist epilepsy centres in the UK. Staff 
approached 129 people based on the study inclusion/exclusion criteria (staff reviewed clinical notes 
of listed patients in advance of clinic attendance to check for potential eligibility). Sixty-two (48%) of 
those approached registered their interest in participating in the study and were contacted. Five 
people subsequently declined to take part, contact was lost with one person and 56 people 
consented. Prior to the interview participants received a copy of the study information leaflet. Before 
the interview commenced, the purpose of the interview, freedom to withdraw, the issues of 
anonymity and risk and audio recording of the interview were discussed; and participants had the 
opportunity to ask any questions and have these answered. Participants then provided written 
consent for participation. Interviews were conducted in participants’ own homes or at an alternate 
venue of their choosing. All interviews were conducted by the same researcher (AR). The majority of 
interviews were between one and two hours in duration. The participant sample comprised 29 males 
and 27 females, with an age range of 20 -76 years (mean age: 40.12 years).  Twenty-three 
participants had a recent epilepsy diagnosis and 33 established epilepsy. Twenty-two were women 
defined as ‘of childbearing potential’, of whom seven had a recent diagnosis and 15 had established 
epilepsy. Further details of the socio-demographic characteristics of the sample are given in Table 1. 
All participants were currently taking anti-epileptic drugs (AEDs). Of the 23 participants with early 
epilepsy 18 were on monotherapy. The two most common AEDs taken by people with early epilepsy 
were lamotrigine and levetiracetam. Of the 33 participants with established epilepsy one third were 
on monotherapy. The two most common AEDs taken by participants with established epilepsy were 
lamotrigine and carbamazepine.  Of the 22 women of childbearing potential, 11 were on 
monotherapy. The two most common AEDs taken by women of childbearing potential were 
lamotrigine and levetiracetam. 
 







Gender = Female 3 2 22 
Mean age (years) 47.6 40.3 34.6 
Occupational status 
Full time work 


































Table 1: Study sample characteristics, Phase 1 
* WOCBP = Woman of childbearing potential. 
Participant inclusion criteria for the Phase 2 survey were: adults self-reporting being aged 18 or over 
and diagnosed with epilepsy by a doctor. For the purposes of the Discrete Choice Experiments 
(DCEs), potential respondents were directed to one of three versions of the questionnaire, 
depending on which of the three patient groups they defined themselves as belonging to (for full 
details of the DCE methods, see 52). As for the qualitative study, survey respondents were provided 
with brief descriptions of each treatment and a statement about the evidence of its effectiveness. 
They were asked first to record whether or not they had any personal experience of trying a specific 
treatment and how helpful they had found it (using a four-point Likert response scale, ‘did not help 
at all’ to ‘helped a lot’); and then to register their agreement/disagreement with each preference 
statement (using a five-point Likert response scale, ‘strongly agree’, ‘agree somewhat’, ‘don’t know’, 
‘disagree somewhat’, ‘strongly disagree’).  Survey respondents were asked to provide basic clinical 
and socio-demographic information about themselves (age, gender, epilepsy duration, current 
seizure frequency/status) to contextualise their responses. 
Data analysis 
Phase 1 interviews were tape-recorded, with agreement of participants, and transcribed verbatim. 
Transcripts were imported into NVivo software (QRS Int Pty Ltd) for ease of management and coding 
of transcript data (54). Early transcripts were read and discussed by AR and AJ. Salient concepts were 
identified through a process of ‘open coding’ (55). Codes were categorised thematically and 
relationships between the themes were identified through a process of constant comparison (56). 
The themes included both in-vivo concepts articulated by participants themselves (55) e.g. ‘a normal 
life’ and researcher-defined concepts such as ‘psychological distress’. Through this process a 
thematic framework was developed and applied to all transcripts. Each participant was assigned a 
unique serial number (PSN). The analysis aimed to identify categories common across all three 
patient subgroups and any specific to each; and to identify any commonalities and/or differences by 
other clinical and non-clinical factors. In the event, patient subgroup did not emerge as critical to 
preferences in the analysis, so is not the focus of the findings reported here.  
Data for the survey were analysed in SPSS (IBM Corporation, Somers, NY) using frequencies and 
descriptive statistics.  
 
Phase 1 Findings 
Introduction to preference findings: What does it mean to live life with epilepsy? 
Epilepsy is not a single clinical condition, but rather a spectrum of seizure severity associated with a 
range of psychosocial impacts (57). While the clinical features of epilepsy are central to the 
experience, epilepsy and its treatment do not occur in a vacuum, but within a unique set of life 
circumstances, exploration of which can help us to understand its differential impact on people’s 
lives (58).  
 
Participants in this study described the different ways that epilepsy intruded in their lives including 
disrupting their working life, social activities, daily routines and relationships and affecting their 
physical and psychological wellbeing. Impact in one area of daily life often had knock-on effects for 
other aspects.  For example, many participants spoke about the wide reaching impact of not being 
allowed to drive, including on getting to work, the type of work they were able to do and the 
organisational aspects of work. Driving was an important aspect of ‘independence’ and having to rely 
on other people was an undesirable outcome of having epilepsy for many participants. The context 
within which loss of the ability to drive was experienced was important, as one participant described:   
 
‘Yes [frustrating] because you are relying - I know it's not important to most people - but you 
are relying on public transport…there is always cancellations, I mean it took me 3.5 hours to 
get to work the other day and I only work in [town] if I had my car it would have took me 20 
minutes…I was so late for work….A lot of posts that are coming up that I apply for I can't have 
because I have had my driving licence ceased, and that has been a huge impact on my life. 
Because now I have to walk a mile and half to the train station and get 2 trains to work, and 
then after work I get 2 trains to the nursery, to pick the kids up and spending 3 hours a day 
commuting’ [PSN 055, Recently diagnosed epilepsy, WOCBP] 
 
The disruption epilepsy brought to daily life was a major contributory factor to participants’ 
psychological status, including feelings of unhappiness, low mood and depression. Some participants 
also attributed their distress to AED treatment, because of the impact of adverse effects on aspects 
of their everyday life. For example, participants cited possible problems with cognitive functioning, 
such as memory problems; and physical problems such as weight gain.   
 
‘The side effects of the Epilim has just knocked me for six….because the weight gain….it is just 
so depressing, it really is, and it’s unbelievable what it does to you.  It does, you know what I 
mean, it knocks your confidence.’ [PSN 006, Established epilepsy, WOCBP] 
An important concept in understanding epilepsy impact was that of ‘a normal life’. Some participants 
referred to this when talking about the benefits of treatment - usually, though not always, linked to 
seizure control. A normal life involved being able to carry on with things as they had been prior to 
experiencing seizures - including continuing as usual in employment, being able to look after 
children/family, and being able to take part in sporting and social activities. While achieving a sense 
of normalcy was often linked to gaining complete seizure control, one participant described how 
even a reduction in the frequency of their seizures and the debilitating after-effects had contributed 
to a sense of ‘normality’ – by extending the time where they were well enough to be with their 
family. The types, as well as the frequency, of seizures participants experienced were also important 
in understanding epilepsy impact (Box 2).  
  
 
 Obviously the seizure happened in work you see, that is a big factor. …. I wanted to see if I could get a 
letter from [hospital] saying [name] is now on medication and he can live a normal life and he is fine 
to do this, he is fine to do that…and then work to say right ok, we will tick our box. Carry on like you 
were before. [PSN 023, Recently diagnosed epilepsy, Male]   
 
Once I am free [of seizures] for a few weeks, a couple of months, then probably [I can] start getting 
back into the old way of life and just not having to worry all the time…you will be able to just live your 
life normally again… I will be able to look after my kids, just not having to have somebody here all the 
time, while my kids are here. [PSN 016, Established epilepsy, Male] 
 
 I got on the gabapentin and it even though it didn’t stop my fits it changed my life drastically….I got 
some sort of what people would call normality because I had never had that before….it gives me 
longer to be me and longer to be with my kids and things like that. [PSN 007, Established epilepsy, 
WOCBP] 
The generalised seizures are by far the most, the ones that have the most impact on my ability to 
function on a daily basis, the partials you can pass off sometimes as just depending on how long they 
go for….the generalised one, the recovery time as well is excessive for me, I need to sleep for hours, 
so, if that happens at work or when you are out, it is a, it can just ruin a day you just lose a day 
basically, which is not good for me. [PSN 056, Recently diagnosed epilepsy, WOCBP] 
 
BOX 2: Living life with epilepsy 
In describing their experience of epilepsy participants frequently referred to their individual 
circumstances – throwing into stark relief the importance of the lived context of epilepsy in 
understanding its impact. Not surprisingly then, this context (including both clinical and social 
factors) was also important in understanding participants’ preferences for treatment.  
Treatment preferences 
In this section we focus specifically on participants’ views, preferences and decisions about specific 
treatments. These included:  (i) Medical treatments (drug treatment, brain surgery, vagal nerve 
stimulation and the ketogenic diet), (ii) psychological treatments (cognitive behaviour therapy and 
aids for memory problems) and (iii) complementary therapies (Meditation, Yoga, Aromatherapy, 
Biofeedback, Chinese herbal medicine and Acupuncture). All participants had experience of 
treatment with anti-epileptic drugs (AEDs), a small number had undergone brain surgery and a few 
had tried or were currently using VNS.  
 
What influenced participants preferences for treatment? 
In considering what was important about treatment and how they felt about different treatment 
options, our participants thought about how their life had been or might be affected by treatment. 
Some referred to their experience of treatment as being effective in stopping seizures, others 
reported examples of treatments either being unsuccessful or having had negative outcomes. The 
likely risks of treatment were a key consideration, those associated with medication withdrawal 
(further seizures) and brain surgery (brain damage and even death) being particularly challenging.  
(i) Medical treatments: Antiepileptic drugs 
It was evident from both the narrative accounts and direct questioning that AEDs were the preferred 
option for most participants and it was only where AED treatment had proven unsuccessful that 
other types of treatment were considered. However, specific decisions including switching AEDs and 
increasing dosages were highly individual, highlighting the importance of both clinical and 
psychosocial contexts of treatment decisions. For example, one participant described how they had 
requested a return to a previous AED when a change to their medication was followed by a return of 
more ‘worrying’ seizures, leading to injury. Another participant had requested of their clinician that 
the dose of their current AED be increased and the introduction of a second AED following failure of 
the current regimen to substantially reduce the frequency of their seizures - for this participant 
reducing anxiety and getting back to driving were key goals of treatment. And while most 
participants were willing to tolerate some negative effects of AEDs in order to achieve seizure 
control, there was a tipping point at which the negative effects of AEDs for daily living outweighed 
any potential gains (Box 3). For those who were seizure-free, whether or not to withdraw from AED 
treatment was another risk issue to be negotiated, given the potential daily life repercussions of a 
relapse to seizures (Box 3).  
I kind of take most side effects if it means that I can get my licence back and become seizure free and 
stop that worry…about fitting and, the side effects of tiredness and mood swings and irritability pale 
into insignificance compared to worrying about making an idiot of yourself in the town centre, by 
collapsing on the floor, or worrying about your daughters hurting themselves or not being able to 
drive. [PSN 054, Recently diagnosed epilepsy, Male]  
 
She [ESN] said to, try and introduce one more [tablet], I literally have tried but I would be in bed by 
6.30 before the kids actually go to bed…I don’t think that’s a life really …so the best medication is the 
one that is going to have less impact your life. [PSN 007, Established epilepsy, WOCBP]  
 
I was taking lamotrigine and it wasn't working by itself, so they put me on another drug….I had no 
idea that I was so - I think aggressive would be the word, until…[business partner] turned round and 
said I can't deal with you snapping at me anymore...I said right ok I will come off it….I felt absolutely 
awful, as you can imagine, which is why I came off the drugs so I have been a lot more ill…but I don't 
care, quite frankly as long as we are ok. [PSN 020, Established epilepsy, WOCBP]  
 
The difficulty then is, ok, I might try without medication but if another seizure results then I can't drive 
again for at least 12 months, and if I have got a young child [husband] works away a lot, and I haven't 
got a vehicle how does that impact me? You know, my family don't live here, they all live far away so I 
can't rely on family to help me get around - so it sounds daft, but one sort of small thing like that has 
so many ramifications….certainly from my point of view it's not a hugely difficult decision because I 
don't really have any side effects on the medication. [PSN 014, Established epilepsy, WOCBP]  
 
Box 3: Preferences about AEDs  
A key theme in the data was that AED side effects (SEs) were an important cause for concern – with 
participants expressing a variety of reasons for their concerns about particular side effects of 
medication. Important sub-themes (reasons for concern described by many participants) were:  
(i) SEs as psychologically distressing 
Side effects experienced as psychologically distressing either had a direct impact on psychological 
wellbeing (AEDs seen to be the cause of feelings of depression/anxiety/agitation) or indirectly (side 
effects associated with other symptoms such as weight gain, hair loss or word-finding difficulties that 
caused further psychological distress.  
(ii) SEs as disrupting functionality 
Many participants spoke about the disruption to daily functioning as a consequence of AED side 
effects. Side effects that were particularly problematic in terms of daily functioning included: 
tiredness, memory problems and difficulties with concentration.  
(iii) SEs as exacerbating other current or past difficulties 
Participants were particularly concerned about side effects that could further exacerbate current or 
past difficulties. Depression was the side effect that most participants found concerning and wished 
to avoid either because they had experienced depression in the past or because they were currently 
experienced bouts of depression. A number of participants also expressed concern about the 
possibility of experiencing depression based on their perception of depression as a debilitating 
condition. Concentration and memory problems, nervousness, dizziness, headaches, tiredness and 
anger were also symptoms participants were concerned about based on their current or past 
experience. For some people, symptoms such as nervousness (stress) and dizziness were identified as 
possible triggers for their seizures and hence their concern that such symptoms might be associated 
with AEDs. Other participants associated some symptoms with having epilepsy (e.g. memory 
problems) and as such were concerned that these symptoms might also be associated with AEDs.  
(iv) SEs as impacting on ‘others’  
Feelings of anger and aggression were of concern to participants because of the perceived impact 
this would have on other people in particular family members. Several described the impact of such 
feelings for personal and work relationships, others described it not being in their nature. For a small 
number of participants depression was also a side effected that they would be concerned about 
because of the perceived impact on close family members.  
(See Box 4). 
(v) Concerns specific to pregnancy 
 
Adverse effects of AEDs had the added concern for women of child bearing potential of risk of harm 
to their unborn child should they become pregnant. As such, treatment decisions in relation to AEDs 
involved an added layer of complexity (see Box 4):  
 
Box 4: Expressed concerns about AED adverse effects 
(ii) Medical Treatments: Surgery 
Risk was a key theme in relation to brain surgery. Because it was seen as a particularly risky option it 
was completely ruled out by some participants. However, participants’ assessments of risk were 
highly contextualised, their individual life circumstances being key (Box 5). In the majority of 
instances where surgery was considered a potential option, it was almost always a last resort, where 
other approaches had proved unsuccessful in controlling seizures adequately or generated other 
difficulties (Box 5). 
 
I am a mum, I said do you think I am going to put myself through this [operation], when there is a risk 
of death, I know there is a risk of death when I have a fit, but I am not actually going to put myself 
into an operation knowing there is a risk of death and I have got a little one, so I said, thank you, but 
no [PSN 003, Established epilepsy, WOCBP].  
 
I still live in hope that, you know, the medication will settle it down. If it doesn't…I would want 
information about what options there are for me because I don't, I am not sure that I want to be 
taking lots and lots of different types of medication....if, you know, they could find what was causing 
it…there might be some other options open to me such as surgery, or this nerve stimulation or 
whatever, and so certainly I would consider those you know if it was possible [PSN 047, Recently 
diagnosed epilepsy, WOCBP]. 
 
It's looking down towards the surgery route now….the medications I have tried, you know, I have 
been up to and around and actually above the maximum dosages….the medications just don't seem 
to have had an impact on the grand mal seizures, the full seizures…actually [I’m] quite pleased …. I’m 
actually having the assessments… I have spoken to two people who have had [type of surgery], and 
it's worked well for them [PSN 031, Established epilepsy, Male].  
Box 5: Preferences in relation to surgery 
Obviously the side effect of this tablet now, it is an increased dosage but it’s stopped, well, it's 
decreased my seizures - but obviously the result of that is obviously the anxiety…you will get that 
with the Keppra and the it's a known side effect…. it's not a nice thing in general, anxiety…. you 
want to get on with things and you want to do things, and you just, but it's building up (PSN 036, 
Established epilepsy, Male).   
Then problems remembering things...I have to say doesn't really affect me at all but, I would start 
to get very worried if I started not being able to remember things…it would just make me feel like 
my brain was going really if that started happening I would seriously have to consider….what is 
going on to be honest (PSN 009, Established epilepsy, Male) 
 
Feelings of anger or aggression - I think that maybe I wouldn't want to have that problem…it 
wouldn't be a bit fair on my wife, she would take the brunt of it wouldn't she (PSN 039, Recently 
diagnosed epilepsy, Male).  
 
‘I wanted to reduce the risk of anything happening to the baby. But I didn’t want to, you know, like 
double my chance of having a fit and losing the baby altogether, if you know what I mean, so I sort 









(iii) Medical Treatments: Vagal Nerve Stimulation (VNS) 
As for brain surgery, risk was an important theme in relation to VNS. Although some participants 
were willing to consider it as a form of treatment VNS, like brain surgery, was generally seen as a 
secondary option; and for some participants, the invasiveness of the procedure and lack of evidence 
of effectiveness in completely controlling seizure meant it was not a viable one. 
(iv) Psychological/Neuropsychological Treatments 
The benefits of psychological and neuropsychological approaches were key themes in the data. Given 
the negative psychosocial consequences of epilepsy described by many participants, access to 
psychological support was considered an important treatment option. Participants advocating 
psychological support (‘having someone to talk to’) considered the main benefits to be in reducing 
distress and helping people to cope with having epilepsy. Some people were also of the view that 
psychological support might help with seizure control, where stress was a trigger factor (Box 6). 
Many participants (including those with more recently diagnosed epilepsy) highlighted the negative 
impact of epilepsy and drug treatment on memory; and so considered help with memory problems 
to be an important treatment option.  For example, one participant described the wide reaching 
impact memory loss was having and the potential serious consequences for their working life, which 
in turn was contributing to the psychological toll of epilepsy (Box 6). 
 
v) Complementary therapies 
Key themes with regard to use of complementary therapies were their value in managing and coping 
with epilepsy. Such therapies, in particular Meditation and Yoga, were viewed as potentially useful in 
reducing stress and aiding relaxation in the context of epilepsy and its effects – and hence were 
particularly valued by participants who considered stress to be a potential seizure trigger. Other 
participants too were interested in these types of therapies, seeing their value as lying in helping 
people to cope with epilepsy and its effects (Box 7). 
 
I think doctors and specialists think about the physical benefits with your medication and stuff like 
that, but I think the psychological issues get very overlooked and they don't get treated - so I think 
with good psychological help, it reduces the amount of fits that you have or the stress that you have 
or the stress that can trigger the fits - so I think it's very beneficial that you have some sort of 
psychological help (PSN 007, Established epilepsy, WOCBP]. 
 
Next I would put problems remembering things, because that really does affect work and it affects 
home life as well - you know, when I am supposed to do things, just everyday things, and I forget to 
do it, it has a huge impact ….if I forget things in work it's serious…God, something could go wrong, 
and something bad could happen…. and all because I forgot to do something.  So that does worry 
me…. and that makes me depressed [PSN 055, Recently diagnosed epilepsy, WOCBP]. 








Yoga, it's not something I have tried myself but….it's something that I might like to try in terms of 
helping to gain a form of relaxation.  As I said before…. stress can be a trigger for seizures, so that can 
be a great way of managing stress [043, Established epilepsy, Male]. 
 
The yoga and the acupuncture, the herbal medicine, meditation, yes, I think I would see that more as 
being a treatment for the way that you feel, rather than controlling your actual condition,… it 
wouldn't cure you of [epilepsy] but it might make you feel better [PSN 052, Recently diagnosed 
epilepsy, WOCBP].  
Box 7: Preferences for complementary therapies 
 
Summing up - the complexity of treatment decisions 
Through the findings presented above we aim to demonstrate the multitude of factors that can 
influence individual treatment decisions. Their experiences of treatment and assessments of 
treatment benefits and adverse consequences clearly influenced participants’ preferences and 
decision-making. In the absence of adverse effects and taking account of the consequences of 
continuing seizures for everyday life, the decision to take AEDs was a relatively straightforward one. 
Where seizures had become intractable and the negative impacts of increasing AED dosage far 
outweighed the potential for achieving seizure control, limiting the disruptive effects of treatment on 
everyday life became a key goal.  
While treatment with AEDs was the preferred option for the majority, some participants, even early 
in their epilepsy trajectory, expressed willingness to consider others, should their seizures not be well 
enough controlled by medication. However, the limited evidence for success of some interventions, 
the risks involved and their perceived ‘invasiveness’ meant other participants were adamant that 
some treatments were not viable options for them. With regard to non-clinical treatments, a 
considerable number of participants highlighted problems with their memory and how this affected 
their everyday life, such that support to improve memory problems was seen as potentially highly 
beneficial. Psychological therapies were also considered important in managing the negative impact 
of epilepsy on sense of wellbeing. Similarly, complementary therapies were considered potentially 
helpful to reduce stress – sometimes identified as a trigger for seizures – and as an aid to relaxation.  
Although used as a means to identify study participants, our analysis of the qualitative material 
highlighted that patient subgroup did not emerge as critical to preferences: all the issues described 
were endorsed by participants across all our sampled groups. However, for one group, women of 
childbearing potential, the complexity of treatment decisions was compounded by preferences over 
contraception and by their understanding of the need to balance potentially competing risks to 
themselves versus any unborn child. As has been shown elsewhere (59) and was clearly articulated 
by the women in this study, they faced the additional dilemma of whether to continue taking AEDs, 
with possible negative effects for pregnancy outcomes, or discontinue AEDs and risk an increased 
frequency of seizures.  
Phase 2 Study Findings 
Four hundred and fourteen people responded to the survey (7 by paper). Of these 401 started, 
though not all completed, the survey questionnaires. The numbers completing the preference 
statements ranged from 323 to 331. 
The median age of the sample was 37 years (range 18-79); and 68% of the respondents were 
female.  The majority of respondents co-habited; and just over half were employed.  The sample was 
predominantly people with an established diagnosis (94%), with a high proportion (56%) of people 
with uncontrolled epilepsy (time since last seizure less than 1 month). Just under half had 
experienced recent changes to their AED regimen (within the last 3 months). Because of the very 
small numbers replying who reported a recent diagnosis of epilepsy, we do not present data on 
respondent characteristics separately for the recently diagnosed and established epilepsy subgroups 
(see Table 2).  
 
 
 Recent diagnosis and 
established epilepsy 
subgroups combined 
Women of childbearing 
potential* 
n Valid % n Valid %  
 
N 262 100.00 139 100.0 
Time since diagnosis  









Established:  1-10 years 63 24.3 52 38.0 
















Female 134 51.1 139 100.0 
White British 191 93.6 109 94.8 
Live alone 37 18.1 10 8.6 
Employed 59 51.8 90 79.0 
Seizure types     
Focal  78 36.1 46 36.8 
Complex focal  95 44.0 60 48.0 
Absences 96 44.4 60 48.0 
Tonic clonic 140 64.8 91 72.8 
Time since last seizure     
Less than 1 month 164 75.2 89 71.8 
Seizure frequency compared to 1 year ago     
Increased 53 24.5 22 17.6 
Constant 97 44.9 63 50.4 
Decreased 66 30.6 40 32.0 
AED in past 3mths     
No change 123 58.6 67 55.4 
Change: seizure control 64 71.9 42 77.8 
Change: adverse events** 30 33.7 19 35.2 
Change: Remission 5 5.6 3 5.6 
Experience of adverse eventsa     
Aggression 20 22.0 11 20.0 
Depression 25 27.5 21 38.2 
Memory Problems 29 31.9 17 30.9 
Change of AED due to Pregnancy concern 39 42.9 27 49.1 
Experience of other treatments for 
epilepsy 
    
Surgery 17 7.9 7 5.7 
VNS 18 8.3 7 5.7 
Table 2.  Phase 2 respondent characteristics 
Note.  *Women of childbearing potential (those who responded “yes” to: “Is there any chance, however remote, that you may 
become pregnant in the future?”).  Data are counts unless otherwise stated.    **Described in questionnaire as “side-effects”.  
aDue to a routing error in the questionnaire, only patients who had experienced a change in their AED in the past 3 months 
responded to the item on experience of adverse events.   
 
Table 3 documents responses to the individual preference items relating to the treatment options of 
surgery, VNS, psychological support and complementary therapies (preferences relating to AEDs 


















Surgery     
I would consider surgery if my seizures could not be 
controlled by medication 
331 35 36.9 71.9 
I would only ever consider surgery as a last resort 330 32.1 33.6 65.8 
I would never want to have surgery because of the risks 
involved** 
328 19.5 18 37.5 
VNS     
I would consider having VNS to help control my seizures 330 30.3 27.3 57.6 
I would not want to try VNS because I think it is too 
invasive 
328 11.9 8.5 20.4 
Psychological support     
There is not enough psychological support available for 
people with epilepsy 
325 22.2 51.7 73.8 
I would like to be offered psychological support to help 
manage my epilepsy 
324 28.7 35.8 64.5 
I think psychological support should be more readily 
available 
325 28.6 52.3 80.9 
Support for memory problems     
I have problems with my memory and would like to know 
what help is available 
327 26.6 54.7 81.3 
Complementary therapies     
I would like to try yoga (in addition to taking medication) 
to help me cope with having epilepsy 
328 25.6 22.6 48.2 
I would like to try acupuncture (in addition to taking 
medication) to help me cope with having epilepsy 
326 18.7 12.6 31.3 
I would like to try meditation (in addition to taking 
medication) to help me cope with having epilepsy 
326 27.3 18.1 45.4 
I would like to try aromatherapy (in addition to taking 
medication) to help me cope with having epilepsy 
323 18.9 14.2 33.1 
Table 3: Agreement rates survey preference statements  
*As described earlier, respondents were asked to answer each preference statement using a 5-point Likert response scale, 
‘strongly agree’, ‘agree somewhat ’, ‘don’t know’, ‘disagree somewhat’, ‘strongly disagree’).  For parsimony, only the %s 
agreeing are shown here. 
**It is interesting to note that some participants who said they would never want to have surgery because of the risks also 
indicated that they would consider surgery if their seizures were uncontrolled by AEDS. 
The majority of survey respondents, over 70%, stated that they would consider surgery if their 
seizures were not sufficiently well controlled by AEDs – but most (66%) also saw surgery as a 
treatment of last resort; and almost two-fifths took the position that they would never want to have 
surgery because of the risks involved.  Just over half of respondents would be willing to try VNS to 
control seizures. Around a half expressed interest in meditation and yoga as potentially useful 
approaches to coping with having epilepsy. Perhaps most importantly, three-quarters of survey 
respondents agreed that psychological support for people with epilepsy was lacking and should be 
made more readily available; with two-thirds keen to avail themselves of it. Equally important, over 
80% wanted support to manage memory problems associated with having epilepsy. There were no 
statistically significant differences in the responses to these statements by women of childbearing 
potential or otherwise. 
 
Discussion 
We used a combination of in-depth qualitative and large-scale quantitative approaches to investigate 
the expressed preferences for treatment of people with epilepsy, both recently diagnosed and 
established, and including a specific patient sub-group, women of childbearing age. The use of this 
methodological ‘triangulation’ (60) helps, we would argue, to enhance the trustworthiness of our 
findings (61), since the issues and concerns presented in the in-depth accounts of Phase 1 
participants were then subject to scrutiny by the much larger number of survey respondents. Their 
subsequent endorsement of key themes identified in the qualitative phase increases the overall 
robustness of our conclusions. Thus, for example, the concerns expressed by phase 1 study 
participants about the risk of harm associated with different treatments were echoed by 
respondents to the survey. Likewise, there was support from both phases of the study for greater 
provision of psychological and neuropsychological support. 
From our qualitative study, key drivers for treatment preferences were the desire to achieve seizure 
freedom and live ‘a normal life’. Whilst, in general, experiencing some negative treatment effects 
was considered a tolerable trade-off for seizure control (see Holmes et al, 52) risk of harm was a key 
concern; and there was a tipping point where the adverse consequences of treatment were seen to 
outweigh any benefits.  For example, surgery was often viewed as particularly risky and a last resort 
treatment due to its potentially catastrophic consequences – a finding reinforced by the survey, 
where two-thirds agreed with the statement that they would only ever consider surgery as a last 
resort.  
Our qualitative study involved 22 women defined as of childbearing potential. Supporting what has 
been reported elsewhere in the literature (59) weighing up the benefits versus the risk of harms of 
treatment was particularly complex for these women - who had to assess potential risks, not only to 
themselves but also to an unborn child. Whilst they, like other participants, had generic concerns 
about treatment options and health care provision more broadly, their decisions concerning 
treatment in the context of epilepsy were inherently more complex. Our data highlight once again 
the need in this group for provision of advice on appropriate contraception, the risks of pregnancy 
with regard to foetal outcomes, and what represents appropriate AED medication. Optimal provision 
of such advice can only be realised if women have access to the relevant specialists before, 
throughout and after pregnancy. 
Among possible options for managing life with epilepsy, psychological support broadly and support 
for memory problems specifically, were highlighted as important aspects of treatment currently of 
very limited availability.  Participants in both phases of the study were keen to stress the need for 
better provision of these two treatment options.  Large numbers of participants across the two study 
phases were also interested in accessing complementary therapies such as yoga, meditation, 
aromatherapy, and traditional Chinese medicines. 
Limitations of our study 
Our conclusions are limited by the relatively small number of participants involved in the second 
phase of our study. For the qualitative investigation, we aimed to recruit 60 individuals, in order to 
reach data saturation; and in the event, we achieved a sample size of 56. For the survey, however, 
from a potentially very large sample (the EA membership database) only 401 individuals responded; 
and analysis showed that responders tended to be people with established epilepsy of some 
duration, who were likely experiencing frequent seizures (56% had had a seizure in the previous 
month) and had switched medications recently, most often owing to lack of efficacy.  As has often 
been argued to be the case in surveys drawing on patient support group membership, it may be that 
they responded to EA’s request for participation for the reason that they were individuals whose 
epilepsy was particularly problematic for them. Further, a significant number (approximately 20%) 
who completed the DCE that formed the first part of the survey failed to continue with completion of 
the section relating to treatment experiences and preferences, perhaps because the DCE was of itself 
quite a lengthy exercise. The survey was an online one, so completion was dependent on access to 
the internet; and the sample was a self-selected one. Thus, for a number of reasons the 
generalizability of our findings may be compromised.  
Further, in both the qualitative study and the survey, those individuals with established epilepsy 
would almost inevitably have had more life and treatment experiences to inform their views and 
preferences than those only recently diagnosed. There is evidence from elsewhere (62), albeit in the 
context of systems of healthcare rather than specific treatments, that having preferences is 
problematic if a person has not experienced the different possible alternatives under comparison, 
since ‘consumers do prefer what they know’. Additionally, treatment preferences are not static, but 
may change both over time and as a result of treatment experience (63). Even among our 
participants with established epilepsy, relatively few had experience of surgery or VNS; or of 
treatments aimed less at managing seizures than managing epilepsy as a lived experience. This needs 
also to be borne in mind when interpreting our findings. 
Not withstanding these limitations, we would suggest that our study is one of few to explore in depth 
the treatment preferences of people with epilepsy. Our findings make clear that patient views about 
the value of and their preferences for treatment need to be considered within their individual life 
context – which will include gender, epilepsy history and characteristics, the physical, psychological 
and life impacts of epilepsy and everyday life circumstances (including life roles and responsibilities). 
How can patient preferences be addressed? 
In considering the answer to the above question, we focus here on what our study has to say about 
non-AED treatment options, since patient preferences around AEDs is dealt with in detail elsewhere 
(52, 62). Despite the limitations previously discussed, there are a number of key messages from this 
study, with implications for patient care. First, exploration of the possibility of surgery for epilepsy as 
a treatment option has highlighted considerable resistance to its use among participants, except in a 
situation of ‘last resort’. Yet, it has been argued that surgery should not be reserved as an option to 
be invoked only when all else fails (65,66). Evidence suggests that not only patients, but clinicians 
also, may take this position, with the result that individuals with pharmaco-resistent epilepsy may be 
subjected to many years of poor seizure control before surgery is proposed. Engel et al (65) note that 
typically, patients are referred for surgery too late to avoid significant disability (and, it follows, 
significant decrements in quality of life). Yet, in the randomised trial these authors report, of early 
surgery in patients with disabling seizures persisting for a maximum of two years following trials of 
two AEDS, 11 of 15 in the surgical group compared to none on the medical group were seizure-free 
during a two-year follow-up period.  There was also a (non-significant) improvement in their QOL 
scores, compared to the medical controls.  These findings support Gilliam’s (67) comment that 
patients need to be given adequate information regarding the relative risks of undergoing surgery 
compared to experiencing recurrent seizures, in order to make fully informed choices. Engel (68) 
notes that technological advances have made surgery a much safer and more efficacious treatment 
option; and this is a message that, our findings would suggest, needs greater discussion with 
potential patient candidates, allowing them to better appreciate its role in epilepsy management.  
Engel (69) has made the point that for patients unwilling to consider or judged unsuitable for surgery, 
‘a variety of treatments‘ are still available. Among those he cites include ones identified of interest to 
participants in our study – namely, complementary therapies and psychological support as a means 
of dealing with the stress of their condition and helping to come to terms with it. In our survey, 
almost four-fifths of participants commented on the paucity of psychological support services; and 
over three-fifths commented on their wish that they themselves be offered such support. Thus, our 
study has identified an area of large unmet need. Though we did not question participants at either 
phase of the study about their psychological status, anxiety and depression are known to be the 
commonest co-morbidities in epilepsy (70,71), both potentially responsive to appropriate treatment 
(19,23,24,26,72). By way of example, the UPLIFT programme (73) used CBT delivered by phone and 
internet in adults with epilepsy with mild to major depression and reported a significant reduction in 
the incidence of major depression in the active intervention group. The current lack of such 
psychological support is therefore an issue of considerable concern.  
Most common among the co-morbidities after anxiety and depression are neuropsychological 
problems, in particular problems with memory. In our own study, memory problems were reported 
by almost a third of survey respondents; and they valued reduction in the risk of memory problems 
more highly than improvements in the probability of seizure remission (52). There are multiple 
potential causes of memory problems in epilepsy – they may be associated with the type of 
underlying lesion or seizures; they may be a side-effect of AEDs; or they may be secondary to mood 
disorders (74). Possible explanations for memory problems therefore need unpicking at an individual 
patient level.  Patients consistently report memory problems as significant (75,76); but, 
unfortunately, despite patients’ concerns they are not routinely addressed in clinical practice.  The 
most significant reason for the poor provision of memory rehabilitation programmes – at least in the 
UK - is the lack of availability of neuropsychological services (Baker, personal communication); but 
PWE may also be too ready to accept memory decrements as an inevitable outcome of epilepsy and 
therefore fail to seek appropriate support. Nonetheless, in our study, over 80% of participants in the 
survey reinforced the clear message from interview informants about the lack of provision and the 
need for greater investment in this treatment option.  
Finally, despite that the lack of evidence of effectiveness was highlighted in the patient information 
provided and though they did not see complementary therapies as contributing directly to seizure 
control, significant numbers of participants in both phases of the study expressed interest in them as 
a means to help them to cope with their epilepsy.  In the qualitative study, most frequently 
mentioned were meditation, yoga, aromatherapy and acupuncture. In the survey, a third of 
respondents were interested in aromatherapy, and just under a half in yoga and meditation. One 
question this raises is to what degree patients are aware that there may be some costs, as well as 
benefits from the use of complimentary therapies; and that evidence in support of their use is 
currently very sparse. The UK Epilepsy Society provides information to patients about the different 
complimentary therapies in which it highlights that some can potentially increase the risk of seizures 
(https://www.epilepsysociety.org.uk/complementary-therapies; accessed 5 March 2017) - so 
patients need to know as much as possible about them. In particular, in the context of our study 
participants’ preferences, they note that some essential oils used in aromatherapy are not 
recommended as they may trigger seizures. The authors of a Cochrane Review (77) concluded, based 
on 17 randomised trials involving over 1500 individuals, that compared to AEDs alone, needle 
acupuncture and catgut implantation at acupoints in combination with AEDs was ineffective in 
achieving seizure freedom, but may be better in achieving satisfactory seizure control. However, 
since the trials considered were small and with high risks of bias, the conclusion was that ‘it remains 
uncertain whether acupuncture is effective and safe for treating PWE.’ Yoga for epilepsy was 
considered, also in a Cochrane Review (78), which included two randomised trials involving 50 adults 
with refractory epilepsy and suggested possible beneficial effects in relation to seizure control. 
However, again, the authors concluded that the evidence was insufficient to support its use and that 
further trials are needed. Finally, a non-randomised study has recently been conducted of the role of 
meditation as a treatment for epilepsy (https://clinicaltrials.gov/ct2/show/NCT00370929; accessed 5 
March 2017), in which the outcomes of interest are not only seizure frequency, but also quality of life 
and specific QOL domains (mood, affect, sleep quality) – these latter outcomes being the ones of 
particular interest to our own study participants. However, no results have been published as yet. 
Though use of complementary therapies may have little impact on seizure frequency, at least 
directly, they may have other important benefits for quality of life in PWE, which needs confirmation 
through conduct of robust clinical trials. 
In conclusion, we would suggest that our study bears witness to the need to understand how patient 
preferences for care align to their personal characteristics and life contexts (39). The author of the 
study alluded to above has commented that epilepsy is a complex condition treatment of which, 
‘relies on precise understanding of patient characteristics’ (79).  Adoption of an ‘ecological model’ 
(80) of patient preferences emphasises that preferences, ‘emerge from various contexts’ including 
not just the clinical encounter, but also family and media exposure. Our study supports these 
arguments. It also emphasises the importance of ensuring that treatment options responsive to 
patient preferences are adequately investigated and those for whom evidence of utility can be 
shown are made more readily available. 
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Appendix 1: Examples of treatment interventions and evidence of effectiveness 
 
Medical Definition Effectiveness 
Surgery for epilepsy ‘There are many different types of 
surgery for epilepsy. The type of surgery 
depends on the type of seizures and the 
area of the brain where seizure begins’. 
(Epilepsy Action) 
Surgery is effective in reducing the 
frequency of seizures and stopping 
seizures altogether in some cases. 
However, the success of surgery is 
dependent on the type of epilepsy 
and the type of surgery (Spencer and 
Huh, 2008).  
Vagal nerve stimulation 
(VNS) 
‘Vagus nerve stimulation (VNS) uses a 
small generator that is implanted under 
the skin below the collar bone. This is 
connected to a lead with two coils at one 
end. The coils are wrapped around the 
vagus nerve at the side of the neck, under 
the skin, during a small operation. The 
generator sends electrical impulses, at 
intervals, to the vagus nerve and then to 
the brain’. (Epilepsy Action). 
Current evidence suggests that 
around two thirds of people 
receiving VNS, experience 30% or 
greater improvement in seizure 
frequency. Seizure improvement 
following VNS is not significantly 
greater then seizure improvement 
with medication (Vonck et al, 2009).  
Psychologically based   
Cognitive behavioural 
therapy (CBT) 
‘CBT is a problem-focused talking 
therapy. CBT helps people to identify 
problems and difficulties in their life and 
to resolve those difficulties by breaking 
them down into their smaller parts 
(situation, thoughts, emotions, physical 
feelings and actions) and by changing 
individual thinking and behaviour and 
emotional response’. (ACT; RCPsych) 
There is some evidence that CBT may 
be beneficial for treating epilepsy 
and its co-morbidities (McLaughlin 
and Farland, 2011).  There are many 
different psychological therapies and 
lack of consistency across studies has 
made establishing treatment 
effectiveness difficult (Ramaratnam 
et al, 2008).  
Complementary   
Yoga 
 
‘Yoga is a physical, mental and spiritual 
discipline’ (Wiki). Different types of Yoga 
involve concentration on breathing 
(controlled breathing), physical exercise 
(stretching and flexing - posture) and 
meditation and relaxation (Epilepsy 
Action & byw).  
Whilst there is some evidence for the 
possible beneficial effects of Yoga for 
epilepsy (Yardi, 2001; Lundgren et 
al., 2008), evidence remains very 
limited (McElroy-Cox, 2009). 
Acupuncture ‘Acupuncture involves treating the whole 
person, body and mind, by using needles, 
and sometimes heat, to stimulate the 
nerve endings. The aim is to improve the 
general state of health, creating a better 
mental, physical and emotional balance’ 
(Epilepsy Action). 
Whilst case study evidence suggests 
potential benefits of acupuncture 
(Yang & Cheng, 2010), there is no 
evidence from more robust research 
methods to support effectiveness of 
acupuncture in treating epilepsy 
(McElroy-Cox, 2009). 
 
